Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Voxar secures Australian PACS (picture archiving and communications system) deal:

This article was originally published in Clinica

Executive Summary

Voxar, the Scottish medical imaging software company, has signed a clinical solutions agreement with Australian medical technology and IT company Central Data Networks (CDN). Under the deal, CDN's CentraRad digital radiology workstation and picture archiving and communications system (PACS) will incorporate Voxar's 3D rendering tools, in which it specialises. The deal seeks to add value to CDN's PACS platform, while extending Voxar's established successes in the 3D PACS sector in Europe, the US and Japan. Edinburgh-based Voxar is Scotland's fastest growing technology company, according to the Deloitte & Touche Technology Fast 50 ranking, published last week; earlier this year it was named one of the EU's top 10 emerging private technology companies at the Tornado Insider UpStart Europe 2002 event.

You may also be interested in...



MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’

The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.

Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company

The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.

Synthekine Joins Quest To Tame IL-2 In Cancer Therapies

First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT069094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel